NASDAQ:SRDX - SurModics Stock Price, Price Target & More

$38.05 +0.60 (+1.60 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$37.45
Today's Range$37.45 - $38.40
52-Week Range$22.35 - $40.30
Volume16,671 shs
Average Volume38,313 shs
Market Capitalization$490.91 million
P/E Ratio74.61
Dividend YieldN/A
Beta0.51

About SurModics (NASDAQ:SRDX)

SurModics logoSurmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. SurModics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:SRDX
CUSIP86887310
Phone952-500-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio3.07%
Quick Ratio2.87%

Price-To-Earnings

Trailing P/E Ratio74.61
Forward P/E Ratio-761.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$73.11 million
Price / Sales6.87
Cash Flow$0.9824 per share
Price / Cash38.73
Book Value$8.41 per share
Price / Book4.52

Profitability

EPS (Most Recent Fiscal Year)$0.51
Net Income$3.92 million
Net Margins0.10%
Return on Equity5.04%
Return on Assets4.16%

Miscellaneous

Employees257
Outstanding Shares13,200,000

SurModics (NASDAQ:SRDX) Frequently Asked Questions

What is SurModics' stock symbol?

SurModics trades on the NASDAQ under the ticker symbol "SRDX."

How were SurModics' earnings last quarter?

SurModics, Inc. (NASDAQ:SRDX) announced its quarterly earnings results on Thursday, February, 8th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.15. The business earned $17.01 million during the quarter, compared to analysts' expectations of $17.69 million. SurModics had a net margin of 0.10% and a return on equity of 5.04%. View SurModics' Earnings History.

What price target have analysts set for SRDX?

5 equities research analysts have issued twelve-month target prices for SurModics' shares. Their forecasts range from $38.00 to $42.00. On average, they expect SurModics' stock price to reach $40.00 in the next twelve months. View Analyst Ratings for SurModics.

What are Wall Street analysts saying about SurModics stock?

Here are some recent quotes from research analysts about SurModics stock:
  • 1. According to Zacks Investment Research, "Surmodics has outperformed its industry in a year's time. Further, solid performance in the In Vitro Diagnostics segment, which gained grounds on the back of strong growth and stabilization across BioFX, microarray and antigen product sales holds promise. Surmodics issued a solid guidance for fiscal 2018. The company's solid initiatives to strengthen research and development programs hold promise. On the flipside, the company witnessed significantly high operating losses. Product sales declined owing to shipment issues, particularly in the Medical Device segment. Further, foreign-exchange woes related to the Creagh Medical buyout have been a major dampener. Surmodics’ drug-coated balloons face stiff competition in niche space. The company’s margins are expected to be under pressure, due to expenses in the Irish facility infrastructure and lower Medical-Device product gross margins." (4/11/2018)
  • 2. Needham & Company LLC analysts commented, "SRDX is undergoing a transition from a supplier of medical device coatings to finished medical device products. In the near-term, this requires heavy R&D investment which has turned SRDX unprofitable. In the long-term, this should expand SRDX’s available market and accelerate its revenue growth. We believe that investors receive an inexpensive call option on SRDX’s DCBs at its current valuation. Given this, we are initiating coverage with a Buy rating." (2/27/2018)

Who are some of SurModics' key competitors?

Who are SurModics' key executives?

SurModics' management team includes the folowing people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 55)
  • Mr. Andrew D. C. LaFrence CPA, VP of Fin. & Information Systems, CFO and Principal Accounting Officer (Age 55)
  • Mr. Bryan K. Phillips, Sr. VP of Legal & HR, Gen. Counsel and Corp. Sec. (Age 47)
  • Mr. Charles W. Olson, Sr. VP of Commercial & Bus. Devel. - Medical Devices (Age 54)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 52)

Has SurModics been receiving favorable news coverage?

Headlines about SRDX stock have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SurModics earned a media sentiment score of 0.10 on Accern's scale. They also assigned news headlines about the company an impact score of 44.33 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of SurModics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SurModics' stock price today?

One share of SRDX stock can currently be purchased for approximately $38.05.

How big of a company is SurModics?

SurModics has a market capitalization of $490.91 million and generates $73.11 million in revenue each year. The company earns $3.92 million in net income (profit) each year or $0.51 on an earnings per share basis. SurModics employs 257 workers across the globe.

How can I contact SurModics?

SurModics' mailing address is 9924 W 74TH ST, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]


MarketBeat Community Rating for SurModics (SRDX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  336
MarketBeat's community ratings are surveys of what our community members think about SurModics and other stocks. Vote "Outperform" if you believe SRDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

SurModics (NASDAQ:SRDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for SurModics in the last 12 months. Their average twelve-month price target is $40.00, suggesting that the stock has a possible upside of 5.12%. The high price target for SRDX is $42.00 and the low price target for SRDX is $38.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $40.00$40.00$40.00$40.00
Price Target Upside: 5.12% upside6.38% upside45.19% upside45.19% upside

SurModics (NASDAQ:SRDX) Consensus Price Target History

Price Target History for SurModics (NASDAQ:SRDX)

SurModics (NASDAQ:SRDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2018Needham & Company LLCReiterated RatingBuy$42.00MediumView Rating Details
3/1/2018SidotiUpgradeNeutral -> BuyLowView Rating Details
2/28/2018Barrington ResearchUpgradeMarket Perform -> OutperformHighView Rating Details
2/28/2018Lake Street CapitalReiterated RatingBuy -> Buy$35.00 -> $38.00LowView Rating Details
6/27/2017AegisInitiated CoverageBuyHighView Rating Details
(Data available from 4/26/2016 forward)

Earnings

SurModics (NASDAQ:SRDX) Earnings History and Estimates Chart

Earnings by Quarter for SurModics (NASDAQ:SRDX)

SurModics (NASDAQ:SRDX) Earnings Estimates

2018 EPS Consensus Estimate: $0.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.01$0.01$0.01
Q2 20181$0.06$0.06$0.06
Q3 20181$0.06$0.06$0.06
Q4 20181$0.07$0.07$0.07

SurModics (NASDAQ SRDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2018Q1 2018($0.05)$0.10$17.69 million$17.01 millionViewN/AView Earnings Details
11/8/2017Q4 2017($0.01)$0.18$16.98 million$20.06 millionViewN/AView Earnings Details
8/3/2017Q3 2017($0.01)$0.09$15.98 million$17.80 millionViewListenView Earnings Details
4/27/2017Q2 2017$0.07$0.05$16.21 million$17.50 millionViewN/AView Earnings Details
2/2/2017Q117$0.09$0.19$15.81 million$17.80 millionViewListenView Earnings Details
11/16/2016Q4 2016$0.09$0.26$16.09 million$18.20 millionViewListenView Earnings Details
7/28/2016Q316$0.12$0.37$16.31 million$19.97 millionViewListenView Earnings Details
5/2/2016Q2$0.09$0.20$14.71 million$16.70 millionViewListenView Earnings Details
1/28/2016Q116$0.17$0.38$14.58 million$16.50 millionViewListenView Earnings Details
11/10/2015Q415$0.19$0.30$15.30 million$17.40 millionViewListenView Earnings Details
8/5/2015Q315$0.21$0.26$14.86 million$15.90 millionViewListenView Earnings Details
4/30/2015Q2$0.20$0.19$14.09 million$14.40 millionViewListenView Earnings Details
1/29/2015Q414$0.21$0.25$14.30 million$14.20 millionViewListenView Earnings Details
11/6/2014Q314$0.25$0.26$14.90 million$15.30 millionViewN/AView Earnings Details
7/31/2014Q214$0.23$0.27$14.84 million$14.62 millionViewListenView Earnings Details
5/1/2014Q114$0.20$0.22$14.40 million$13.60 millionViewListenView Earnings Details
1/30/2014Q413$0.21$0.21$14.15 million$13.90 millionViewListenView Earnings Details
11/5/2013Q313$0.22$0.26$14.32 million$14.30 millionViewListenView Earnings Details
7/31/2013Q3 2013$0.21$0.22$15.03 million$14.29 millionViewListenView Earnings Details
5/7/2013Q2 2013$0.21$0.20$13.92 million$13.70 millionViewListenView Earnings Details
1/30/2013Q1 2013$0.18$0.29$13.63 million$13.85 millionViewListenView Earnings Details
11/6/2012Q412$0.17$0.17$13.83 million$13.80 millionViewN/AView Earnings Details
8/1/2012$0.14$0.17ViewN/AView Earnings Details
5/8/2012$0.15$0.14ViewN/AView Earnings Details
2/6/2012Q1 2012$0.11$0.11ViewN/AView Earnings Details
11/3/2011$0.05$0.06ViewN/AView Earnings Details
8/3/2011$0.04$0.13ViewN/AView Earnings Details
4/27/2011$0.08ViewN/AView Earnings Details
1/26/2011$0.05ViewN/AView Earnings Details
11/10/2010Q4 2010$0.13($0.05)ViewN/AView Earnings Details
7/28/2010Q3 2010$0.14$0.11ViewN/AView Earnings Details
4/28/2010Q2 2010$0.16$0.10ViewN/AView Earnings Details
1/27/2010Q1 2010$0.19$0.11ViewN/AView Earnings Details
11/4/2009Q4 2009$0.20$0.16ViewN/AView Earnings Details
7/29/2009Q3 2009$0.21$0.20ViewN/AView Earnings Details
4/29/2009Q2 2009$0.21$0.24ViewN/AView Earnings Details
1/28/2009Q1 2009$0.26$0.48ViewN/AView Earnings Details
11/5/2008Q4 2008$0.28$0.20ViewN/AView Earnings Details
7/23/2008Q3 2008$0.31$0.26ViewN/AView Earnings Details
4/23/2008Q2 2008$0.30$0.28ViewN/AView Earnings Details
1/23/2008Q1 2008$0.32$0.31ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

SurModics (NASDAQ:SRDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

SurModics (NASDAQ SRDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 84.12%
Insider Trading History for SurModics (NASDAQ:SRDX)
Institutional Ownership by Quarter for SurModics (NASDAQ:SRDX)

SurModics (NASDAQ SRDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2018Joseph J. StichVPSell1,000$33.53$33,530.00View SEC Filing  
12/11/2017Joseph J StichVPSell1,000$30.18$30,180.0046,450View SEC Filing  
9/15/2017Charles W OlsonVPSell801$27.85$22,307.8526,585View SEC Filing  
9/11/2017Joseph J. StichVPSell1,000$27.28$27,280.00View SEC Filing  
8/7/2017Gary R MaharajCEOSell5,000$25.75$128,750.00126,807View SEC Filing  
7/3/2017Gary R MaharajCEOSell5,000$28.03$140,150.00131,807View SEC Filing  
6/16/2017Bryan K PhillipsSVPSell1,226$24.85$30,466.1029,208View SEC Filing  
6/9/2017Joseph J StichVPSell1,000$25.31$25,310.0040,672View SEC Filing  
6/5/2017Gary R MaharajCEOSell2,702$25.09$67,793.18136,807View SEC Filing  
4/3/2017Gary R. MaharajCEOSell584$25.00$14,600.00View SEC Filing  
3/6/2017Joseph J. StichVPSell1,000$24.73$24,730.00View SEC Filing  
12/22/2016Charles W OlsonVPSell1,201$26.00$31,226.0027,386View SEC Filing  
12/8/2016Charles W OlsonVPSell3,699$26.02$96,247.9828,587View SEC Filing  
12/5/2016Joseph J StichVPSell1,000$23.97$23,970.0042,362View SEC Filing  
12/2/2016Bryan K PhillipsSVPSell1,264$23.90$30,209.6029,170View SEC Filing  
11/25/2016Charles W OlsonVPSell500$26.02$13,010.0027,245View SEC Filing  
11/7/2016Gary R MaharajCEOSell5,000$25.22$126,100.00130,207View SEC Filing  
10/3/2016Gary R. MaharajCEOSell5,000$29.55$147,750.00View SEC Filing  
8/17/2016Charles W OlsonVPSell9,936$28.98$287,945.2833,098View SEC Filing  
8/15/2016Susan E. KnightDirectorSell1,548$28.64$44,334.72View SEC Filing  
8/1/2016Charles W OlsonVPSell12,500$27.08$338,500.0035,531View SEC Filing  
6/14/2016Bryan K PhillipsSVPSell1,816$23.44$42,567.0425,350View SEC Filing  
6/10/2016Joseph J StichVPSell1,000$23.33$23,330.0023,492View SEC Filing  
5/27/2016Susan E KnightDirectorSell1,001$22.71$22,732.7116,470View SEC Filing  
3/4/2016Timothy J ArensVPSell10,291$18.43$189,663.139,196View SEC Filing  
12/4/2015Joseph J StichVPSell1,000$21.18$21,180.0021,464View SEC Filing  
9/4/2015Joseph J StichVPSell1,000$23.57$23,570.0022,464View SEC Filing  
6/5/2015Joseph J StichVPSell1,000$23.84$23,840.00View SEC Filing  
5/22/2015Bryan K PhillipsSVPSell7,293$25.25$184,148.25View SEC Filing  
12/29/2014Charles W OlsonVPSell5,083$21.98$111,724.34View SEC Filing  
12/8/2014Charles W OlsonVPSell3,365$21.66$72,885.90View SEC Filing  
11/19/2014Timothy J ArensVPSell10,330$21.02$217,136.60View SEC Filing  
5/8/2014Susan KnightDirectorBuy1,500$20.36$30,540.004,800View SEC Filing  
12/4/2013Bryan PhillipsSVPSell16,236$22.95$372,616.2016,233View SEC Filing  
5/15/2013Mark A LehmanInsiderSell1,693$26.55$44,949.15View SEC Filing  
8/10/2012Value Lp StarboardMajor ShareholderSell257,560$17.74$4,569,114.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

SurModics (NASDAQ SRDX) News Headlines

Source:
DateHeadline
FDA clears Surmodic low-profile catheterFDA clears Surmodic' low-profile catheter
seekingalpha.com - April 23 at 4:01 PM
BRIEF-Surmodics Announces FDA Clearance Of A New .018” Low-Profile Pta Balloon Dilation CatheterBRIEF-Surmodics Announces FDA Clearance Of A New .018” Low-Profile Pta Balloon Dilation Catheter
www.reuters.com - April 23 at 9:43 AM
SurModics, Inc. (SRDX) Receives Consensus Recommendation of "Buy" from AnalystsSurModics, Inc. (SRDX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 7:24 PM
BidaskClub Lowers SurModics (SRDX) to HoldBidaskClub Lowers SurModics (SRDX) to Hold
www.americanbankingnews.com - April 16 at 12:19 AM
SurModics (SRDX) Downgraded by ValuEngine to "Sell"SurModics (SRDX) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 14 at 8:01 PM
Edited Transcript of SRDX presentation 27-Mar-18 6:30pm GMTEdited Transcript of SRDX presentation 27-Mar-18 6:30pm GMT
finance.yahoo.com - April 12 at 11:00 AM
SurModics (SRDX) Downgraded to "Hold" at Zacks Investment ResearchSurModics (SRDX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 2:53 PM
SRDX or HAE: Which is a Better Medical Product Stock?SRDX or HAE: Which is a Better Medical Product Stock?
www.zacks.com - April 9 at 10:18 AM
Heres Why You Should Invest in Surmodics (SRDX) Right NowHere's Why You Should Invest in Surmodics (SRDX) Right Now
finance.yahoo.com - April 4 at 5:35 PM
Here's Why You Should Invest in Surmodics (SRDX) Right NowHere's Why You Should Invest in Surmodics (SRDX) Right Now
finance.yahoo.com - April 4 at 5:35 PM
SurModics (SRDX) Upgraded to "Buy" by ValuEngineSurModics (SRDX) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - April 3 at 12:00 AM
Can The Uptrend Continue for Surmodics (SRDX)?Can The Uptrend Continue for Surmodics (SRDX)?
finance.yahoo.com - April 1 at 10:11 AM
SurModics (SRDX) Receives Buy Rating from Needham & Company LLCSurModics (SRDX) Receives Buy Rating from Needham & Company LLC
www.americanbankingnews.com - March 27 at 5:44 PM
SurModics (SRDX) Lifted to "Buy" at BidaskClubSurModics (SRDX) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM
SurModics (SRDX) Upgraded to "Hold" by BidaskClubSurModics (SRDX) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - March 25 at 1:58 PM
SurModics, Inc. (SRDX) Receives Consensus Rating of "Buy" from AnalystsSurModics, Inc. (SRDX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 24 at 7:33 PM
Head-To-Head Contrast: SurModics (SRDX) versus Cardiovascular Systems (CSII)Head-To-Head Contrast: SurModics (SRDX) versus Cardiovascular Systems (CSII)
www.americanbankingnews.com - March 23 at 1:16 AM
Surmodics to Present at Upcoming Investor ConferencesSurmodics to Present at Upcoming Investor Conferences
finance.yahoo.com - March 15 at 9:59 AM
SurModics, Inc. (SRDX) VP Sells $33,530.00 in StockSurModics, Inc. (SRDX) VP Sells $33,530.00 in Stock
www.americanbankingnews.com - March 13 at 8:51 PM
SurModics (SRDX) vs. Exactech (EXAC) Critical ComparisonSurModics (SRDX) vs. Exactech (EXAC) Critical Comparison
www.americanbankingnews.com - March 12 at 3:08 PM
Landauer (LDR) and SurModics (SRDX) Head-To-Head ReviewLandauer (LDR) and SurModics (SRDX) Head-To-Head Review
www.americanbankingnews.com - March 4 at 7:08 PM
BidaskClub Upgrades SurModics (SRDX) to "Hold"BidaskClub Upgrades SurModics (SRDX) to "Hold"
www.americanbankingnews.com - March 3 at 10:02 PM
SurModics (SRDX) & Inogen (INGN) Financial ContrastSurModics (SRDX) & Inogen (INGN) Financial Contrast
www.americanbankingnews.com - March 1 at 3:08 PM
SurModics (SRDX) Upgraded by Sidoti to BuySurModics (SRDX) Upgraded by Sidoti to Buy
www.americanbankingnews.com - March 1 at 12:30 PM
Abbott to Strengthen Vascular Care Arm With Surmodics DealAbbott to Strengthen Vascular Care Arm With Surmodics Deal
www.zacks.com - March 1 at 9:43 AM
SurModics (SRDX) Upgraded at Barrington ResearchSurModics (SRDX) Upgraded at Barrington Research
www.americanbankingnews.com - February 28 at 7:58 PM
SurModics (SRDX) Price Target Raised to $38.00 at Lake Street CapitalSurModics (SRDX) Price Target Raised to $38.00 at Lake Street Capital
www.americanbankingnews.com - February 28 at 4:44 PM
SurModics (SRDX) Research Coverage Started at Needham & Company LLCSurModics (SRDX) Research Coverage Started at Needham & Company LLC
www.americanbankingnews.com - February 27 at 10:48 PM
SurModics, Inc. (SRDX) Receives Average Rating of "Hold" from BrokeragesSurModics, Inc. (SRDX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 9:30 PM
Surmodics, Abbott ink licensing deal worth up to $92MSurmodics, Abbott ink licensing deal worth up to $92M
finance.yahoo.com - February 27 at 4:34 PM
SurModics (SRDX) Downgraded to Sell at BidaskClubSurModics (SRDX) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - February 18 at 1:00 PM
Surmodics to Host Virtual Annual Meeting of ShareholdersSurmodics to Host Virtual Annual Meeting of Shareholders
finance.yahoo.com - February 13 at 8:45 AM
SurModics (SRDX) Upgraded at Zacks Investment ResearchSurModics (SRDX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 9 at 8:58 PM
SurModics (SRDX) Releases Quarterly  Earnings Results, Beats Estimates By $0.15 EPSSurModics (SRDX) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS
www.americanbankingnews.com - February 9 at 6:26 PM
Surmodics (SRDX) Beats on Earnings in Q1, Guidance SolidSurmodics (SRDX) Beats on Earnings in Q1, Guidance Solid
www.zacks.com - February 9 at 8:49 AM
SurModics reports 1Q lossSurModics reports 1Q loss
finance.yahoo.com - February 8 at 9:18 AM
Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 GuidanceSurmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance
finance.yahoo.com - February 8 at 9:18 AM
Head to Head Survey: LDR (LDRH) vs. SurModics (SRDX)Head to Head Survey: LDR (LDRH) vs. SurModics (SRDX)
www.americanbankingnews.com - February 1 at 5:12 AM
Surmodics to Webcast First Quarter Fiscal 2018 Earnings Conference Call on February 8Surmodics to Webcast First Quarter Fiscal 2018 Earnings Conference Call on February 8
finance.yahoo.com - January 30 at 9:03 AM
BRIEF-Surmodics Receives FDA Clearance For Telemark Peripheral Support MicrocatheterBRIEF-Surmodics Receives FDA Clearance For Telemark Peripheral Support Microcatheter
www.reuters.com - January 22 at 5:22 PM
Surmodics Receives 510(K) Clearance for Telemark™ Coronary/Peripheral Support Microcatheter from the U.S. Food and Drug AdministrationSurmodics Receives 510(K) Clearance for Telemark™ Coronary/Peripheral Support Microcatheter from the U.S. Food and Drug Administration
finance.yahoo.com - January 22 at 5:22 PM
SurModics (SRDX) Rating Increased to Sell at BidaskClubSurModics (SRDX) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - January 14 at 9:38 PM
Financial Survey: Cytori Therapeutics (CYTX) & SurModics (SRDX)Financial Survey: Cytori Therapeutics (CYTX) & SurModics (SRDX)
www.americanbankingnews.com - January 13 at 5:06 PM
Surmodics (SRDX) Poised on Core Business Amid Forex WoesSurmodics (SRDX) Poised on Core Business Amid Forex Woes
finance.yahoo.com - January 11 at 11:36 AM
New Strong Sell Stocks for January 8thNew Strong Sell Stocks for January 8th
finance.yahoo.com - January 8 at 9:05 AM
K2M Group (KTWO) and SurModics (SRDX) Head to Head SurveyK2M Group (KTWO) and SurModics (SRDX) Head to Head Survey
www.americanbankingnews.com - January 6 at 3:36 PM
SurModics (SRDX) Rating Lowered to Strong Sell at BidaskClubSurModics (SRDX) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - December 29 at 6:32 AM
Critical Analysis: SurModics (SRDX) vs. DENTSPLY SIRONA (XRAY)Critical Analysis: SurModics (SRDX) vs. DENTSPLY SIRONA (XRAY)
www.americanbankingnews.com - December 27 at 1:16 PM
SurModics, Inc. (SRDX) VP Joseph J. Stich Sells 1,000 SharesSurModics, Inc. (SRDX) VP Joseph J. Stich Sells 1,000 Shares
www.americanbankingnews.com - December 19 at 9:48 PM
Head to Head Comparison: SurModics (SRDX) & Its RivalsHead to Head Comparison: SurModics (SRDX) & Its Rivals
www.americanbankingnews.com - December 19 at 7:10 PM

SEC Filings

SurModics (NASDAQ:SRDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

SurModics (NASDAQ:SRDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

SurModics (NASDAQ SRDX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.